

# Biodegradable Nanoparticles: A Platform for Lipophilic Drugs Delivery

Dr Fabio Sonvico  
University of Technology  
Sydney, Australia



Fabio Sonvico, born in Como (Italy), the 9th of December 1974, is Associate Professor at the Department of Pharmacy of the University of Parma (Italy). He is member of the Board of Teaching of the PhD Programme in PhD programme "Drugs, Biomolecules and Health Products" (2015-2016), of the Program Committee of the Master (II level) in Pharmaceutical Technology and Regulatory Affairs (2015-2016), and also the Quality System Manager (2015-2016) of the course in Chemistry and Pharmaceutical Technology and of the Interdepartmental Center for Health Products – Biopharmanet TEC (2015-2016), an accredited laboratory part of the High Technology Network of the Emilia Romagna Region (Italy). Current research interests include the design and development of innovative drug delivery systems for unmet clinical needs using biodegradable micro- and nanoparticles, with a special emphasis on the nasal and pulmonary administration. Fabio Sonvico graduated at the University of Pavia (Italy) in Chemistry and Pharmaceutical Technologies in 1999. His Master Thesis was carried out in collaboration with Bayer Italia on "Near Infra Red Spectroscopy application to QA of solid dosage forms". In 2004 he received his Ph.D. from University of Parma (Italy) and University of Paris XI (France). His research project focused on "Functionalised metal nanoparticles for the treatment of solid tumors" and had as supervisors Prof. Paolo Colombo and Prof. Patrick Couvreur. During his Ph.D. he obtained a grant from the French Association for the Research on Cancer (AIRC) to support his research. In 2005 he was researcher of the Italian Research Council (CNR) based at the National Institute of the Physics of the Matter (INFN, Parma). From the end 2005 till 2012 he was Assistant Professor at the Pharmaceutical Department of the University of Parma. From 2012 to 2014 he was Senior Lecturer at the Graduate School of Health of the University of Technology Sydney (Australia). In 2012, he received the UTS Early Career Researcher Grant and he has been accepted as visiting scientist at the Australian National Measurement Institute (Lindfield, Australia). In 2015, he started a project in collaboration with the Universidade Federal do Rio Grande do Sul (Brazil) funded by the CNPq entitled "Surface-modified nanocapsules for the nasal delivery of poorly soluble drugs: a strategy to treat neurodegenerative diseases" - Funding by CNPq-Brazil Minister of Science, Technology and Innovation, number PVE 401196/2014-3"

In 2016, he has been nominated Representative for the University of Parma in the Board of Directors of the National Interuniversity Consortium for Innovative Pharmaceutical Technologies - TEFARCO Innova and subsequently has been elected Vice Director. In 2016, he has been appointed by the pharmaceutical company PlumeStars as Scientific Expert for the development and registration of the Orphan Drug Hyalcis to treat mesothelioma. Since December 2016, he is serving in the Executive Committee of the European Federation of Pharmaceutical Sciences (EUFEPS) as Treasurer. He is author of more than 70 scientific papers (H-index 19), 5 book chapters and 6 patents related to innovative pharmaceutical formulations, some applied in products marketed in Italy.